このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Global Blood Therapeutics マネジメント
マネジメント 基準チェック /44
Global Blood Therapeutics'の CEO はTed Loveで、 Jun2014年に任命され、 の在任期間は 8.33年です。 の年間総報酬は$ 8.19Mで、 8.7%給与と91.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.37%を直接所有しており、その価値は$ 63.19M 。経営陣と取締役会の平均在任期間はそれぞれ6.5年と5.8年です。
主要情報
Ted Love
最高経営責任者
US$8.2m
報酬総額
| CEO給与比率 | 8.7% |
| CEO在任期間 | 8.3yrs |
| CEOの所有権 | 1.4% |
| 経営陣の平均在職期間 | 6.5yrs |
| 取締役会の平均在任期間 | 5.8yrs |
経営陣の近況
Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29Health Check: How Prudently Does Global Blood Therapeutics (NASDAQ:GBT) Use Debt?
Dec 03CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$322m |
| Mar 31 2022 | n/a | n/a | -US$310m |
| Dec 31 2021 | US$8m | US$716k | -US$303m |
| Sep 30 2021 | n/a | n/a | -US$277m |
| Jun 30 2021 | n/a | n/a | -US$266m |
| Mar 31 2021 | n/a | n/a | -US$249m |
| Dec 31 2020 | US$18m | US$661k | -US$248m |
| Sep 30 2020 | n/a | n/a | -US$282m |
| Jun 30 2020 | n/a | n/a | -US$286m |
| Mar 31 2020 | n/a | n/a | -US$291m |
| Dec 31 2019 | US$10m | US$597k | -US$267m |
| Sep 30 2019 | n/a | n/a | -US$220m |
| Jun 30 2019 | n/a | n/a | -US$199m |
| Mar 31 2019 | n/a | n/a | -US$182m |
| Dec 31 2018 | US$10m | US$569k | -US$174m |
| Sep 30 2018 | n/a | n/a | -US$166m |
| Jun 30 2018 | n/a | n/a | -US$152m |
| Mar 31 2018 | n/a | n/a | -US$135m |
| Dec 31 2017 | US$8m | US$520k | -US$117m |
| Sep 30 2017 | n/a | n/a | -US$103m |
| Jun 30 2017 | n/a | n/a | -US$95m |
| Mar 31 2017 | n/a | n/a | -US$89m |
| Dec 31 2016 | US$1m | US$479k | -US$82m |
| Sep 30 2016 | n/a | n/a | -US$71m |
| Jun 30 2016 | n/a | n/a | -US$65m |
| Mar 31 2016 | n/a | n/a | -US$58m |
| Dec 31 2015 | US$2m | US$438k | -US$51m |
報酬と市場: Tedの 総報酬 ($USD 8.19M ) は、 US市場 ($USD 6.76M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Tedの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Ted Love (63 yo)
8.3yrs
在職期間
US$8,193,309
報酬
Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 8.3yrs | US$8.19m | 1.37% $ 63.2m | |
| CFO & Principal Accounting Officer | 6.5yrs | US$2.76m | 0.040% $ 1.8m | |
| Chief Business & Strategy Officer | 7.5yrs | US$2.73m | 0.37% $ 17.2m | |
| Chief Commercial Officer | 4.6yrs | US$2.75m | 0.084% $ 3.9m | |
| Executive VP and Head of Research & Development | 1.4yrs | US$2.98m | 0.0089% $ 409.5k | |
| Founder & Advisor | 11.8yrs | データなし | データなし | |
| Founder & Advisor | 11.8yrs | データなし | データなし | |
| Founder & Advisor | 11.8yrs | データなし | データなし | |
| Executive Vice President of Operations | 2.5yrs | データなし | 0.062% $ 2.9m | |
| Senior Director of Corporate Communications & Investor Relations | no data | データなし | データなし | |
| Chief Legal Officer & Secretary | 6yrs | US$5.93m | 0.064% $ 3.0m | |
| Senior VP & Head of Corporate Communications | 3.8yrs | データなし | データなし |
6.5yrs
平均在職期間
60yo
平均年齢
経験豊富な経営陣: GBTの経営陣は経験豊富で経験豊富です（平均在職期間は6.5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 9.1yrs | US$8.19m | 1.37% $ 63.2m | |
| Lead Independent Director | 7.5yrs | US$348.28k | 0.056% $ 2.6m | |
| Independent Director | 4.8yrs | US$320.78k | 0.017% $ 783.3k | |
| Independent Director | 2.4yrs | US$313.28k | 0.013% $ 618.8k | |
| Independent Director | 6.7yrs | US$318.28k | 0.039% $ 1.8m | |
| Independent Director | 7.1yrs | US$310.78k | 0.013% $ 623.9k | |
| Independent Director | 6.8yrs | US$333.28k | 0.0098% $ 454.8k | |
| Independent Director | 3.8yrs | US$316.36k | 0.0080% $ 368.3k | |
| Advisor & Director Emeritus | less than a year | US$308.28k | 0.058% $ 2.7m | |
| Independent Director | 1.6yrs | US$735.61k | 0.0049% $ 226.5k |
5.8yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: GBTの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。